Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Blonde, Lawrence; Rosenstock, Julio; Frias, Juan; Birkenfeld, Andreas L.; Niemoeller, Elisabeth; Souhami, Elisabeth; Ji, Chen; Del Prato, Stefano; Aroda, Vanita R.

dc.contributor.author	Birkenfeld, Andreas L.
dc.date.accessioned	2021-08-16T09:07:36Z
dc.date.available	2021-08-16T09:07:36Z
dc.date.issued	2021
dc.identifier.issn	1935-5548
dc.identifier.uri	http://hdl.handle.net/10900/117926
dc.language.iso	en	de_DE
dc.publisher	Amer Diabetes Assoc	de_DE
dc.relation.uri	http://dx.doi.org/10.2337/dc20-2023	de_DE
dc.subject.ddc	610	de_DE
dc.title	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20210512015105_00662
utue.publikation.seiten	774-780	de_DE
utue.personen.roh	Blonde, Lawrence
utue.personen.roh	Rosenstock, Julio
utue.personen.roh	Frias, Juan
utue.personen.roh	Birkenfeld, Andreas L.
utue.personen.roh	Niemoeller, Elisabeth
utue.personen.roh	Souhami, Elisabeth
utue.personen.roh	Ji, Chen
utue.personen.roh	Del Prato, Stefano
utue.personen.roh	Aroda, Vanita R.
dcterms.isPartOf.ZSTitelID	Diabetes Care	de_DE
dcterms.isPartOf.ZS-Issue	3	de_DE
dcterms.isPartOf.ZS-Volume	44	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE